Valiant Organics exits DVLLP, to receive Valiant Laboratories shares
Valiant Organics Limited's Board approved exiting Dhanvallabh Ventures LLP (DVLLP). The company will receive 1,86,07,531 equity shares of Valiant Laboratories Limited as consideration. This material related party transaction will be at fair market value. DVLLP's FY26 turnover was ₹0.3756 crore and net worth was ₹83.79 crore.
The transaction involves a material related party transaction and a change in the company's partnership status, which could have strategic implications. The value of the shares received will determine the ultimate financial impact.
The company is exiting a partnership and receiving shares in another entity. While this is a significant corporate action, it does not inherently represent a positive or negative financial outcome without further context on the value of the shares received relative to the partnership interest.
Valiant Organics Limited announced that its Board of Directors, in a meeting held on May 19, 2026, approved the company's cessation as a partner in Dhanvallabh Ventures LLP (DVLLP). This move is subject to requisite shareholder approvals, including a special resolution.
As part of this cessation, Valiant Organics will receive 1,86,07,531 equity shares of Valiant Laboratories Limited as consideration. This transaction is considered a material related party transaction, approved by the Audit Committee and the Board, and will be conducted at fair market value on an arm's length basis, supported by a valuation report from GBCA & Associates LLP dated May 19, 2026.
DVLLP's turnover for Fiscal 2026 was ₹0.3756 crore (0.05% of consolidated turnover), and its net worth was ₹83.79 crore (11.34% of consolidated net worth). The definitive documents for this transaction are expected to be finalized and executed upon receipt of all necessary approvals. The completion of the transaction is anticipated within 60 days of shareholder approval, with the effective date to be specified in the definitive agreements. The Board meeting commenced at 7:35 PM IST and concluded at 8:10 PM IST.
What to do with a filing like this
Valiant Organics Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Organics Limited. Read the original for the full detail.